For more than 60 years, the ventriculoperitoneal (VP) shunt has remained the primary treatment for hydrocephalus. Its introduction marked an important breakthrough – the first time we could address elevated intracranial pressure caused by impaired cerebrospinal fluid (CSF) drainage. Yet even as shunt technology has evolved, a critical limitation has persisted: a CSF shunt placement remains an invasive procedure and shunt systems are prone to high rates of complications including overdrainage of CSF, catheter obstruction, cerebral hemorrhage and post-operative infection, often requiring revision surgeries. These surgical and postoperative risks mean that many medically complex, elderly, or fragile patients are not considered candidates for treatment, even when they have a condition with a well established treatment option.

This points to a challenge for the neurological community: ensuring that proven therapies can be delivered safely and accessibly to the patients who need them. The opportunity ahead lies not only in what we innovate, but in how broadly those innovations can reach.

That is where endovascular innovation begins to change the story.

Over the past few decades, advancements in endovascular surgery have enabled minimally invasive treatment options for a range of vascular conditions including stroke, aneurysm, and carotid artery disease – prioritizing catheter-based access rather than open procedures. These same principles now have the potential to expand access to venous neurological treatments, reducing procedural risk and broadening eligibility for patients who were previously excluded from life-changing surgical options.

The Shift Toward Endovascular Innovation

Endovascular neurosurgery, also referred to as neurointerventional or cerebrovascular surgery, applies the same minimally invasive principles to the brain and spinal cord. Using catheter-based navigation, real-time fluoroscopic and digital imaging, clinicians can access deep neurovascular structures through entry points no larger than a few millimeters. Rather than opening the skull, these techniques use the body’s natural vascular pathways, dramatically reducing trauma to surrounding tissue, or as one neurosurgeon described, “reducing collateral damage.”

What began as a way to treat vascular conditions has evolved into a broader therapeutic platform. In ischemic stroke, mechanical thrombectomy showed that endovascular access could not only improve functional recovery but expand eligibility – reaching patients who were once considered too high-risk or too late to treat.[i] Similar endovascular approaches have transformed care for aneurysms, carotid artery disease, and arteriovenous malformations, often replacing neurosurgical procedures entirely.

Now, those same principles are beginning to extend to neurological conditions that have historically required open surgery – including hydrocephalus.

Impact on Vulnerable Populations

Minimally invasive neurovascular procedures hold particular promise for patients who face higher risks with traditional neurosurgical procedures, especially elderly and pediatric populations. These groups are not excluded from conventional treatment, but they often require more cautious decision-making because of factors such as age-related fragility or underlying comorbidities.

In older adults with normal pressure hydrocephalus (NPH), studies have suggested that endovascular shunting may help improve symptoms such as gait impairment, cognitive decline, and bladder control issues, while potentially reducing procedure related trauma, hospitalization time, and postoperative complications compared with conventional shunt surgery.

For pediatric patients, minimizing disruption to developing tissues, limiting exposure to prolonged anesthesia, and reducing the need for intensive postoperative care are critical considerations that may influence long-term developmental outcomes. These minimally invasive approaches could offer additional treatment pathways that better fit the needs of growing patients.

In both groups, the goal is not to replace existing treatment – but to expand the range of safe, viable options that align with their clinical and real-world realities.

Clinical and Economic Ripple Effects

The impact of minimally invasive neurovascular approaches extends beyond the individual procedure and into the broader healthcare system. Reduced hospitalization times, lower complication and revision rates, reduced post-operative hospitalizations and faster recovery can help decrease overall care costs and ease the burden of hospital resources. For example, the implementation of specialized neurovascular programs has been shown to decrease length of stay and reduce per-visit costs by up to 12.5%.[ii]

As certain procedures shift from inpatient to outpatient or office-based settings, health systems are beginning to see additional gains in operational efficiency. These models support high-quality care with lower overhead, while also improving patient convenience, satisfaction, and access (particularly in community and regional care settings).

The Road Ahead: Integration and Personalization
Personalized medicine is also gaining momentum. By tailoring intervention strategies to a patient’s individual anatomy and disease characteristics, clinicians can better predict responses, minimize unnecessary interventions, and improve outcomes. This approach is particularly valuable in complex conditions such as hydrocephalus and neurodegenerative diseases, where variability in response to treatment can vary between patients.

At its core, the shift toward minimally invasive, endovascular approaches represents more than just a procedural evolution; it reflects broader transformation in how neurological care can be delivered: with greater precision, safety, and expanded access.

For healthcare providers, health systems, and industry leaders, the opportunity extends beyond developing new technologies. It will require investment in training, infrastructure, regulatory alignment, and reimbursement frameworks that support scalable and sustainable adoption. If successfully implemented, these advances have the potential to not only create better outcomes, but also a more efficient, equitable, and innovative neurological care ecosystem.

References:

[i] Vidale, S., Longoni, M., Valvassori, L., & Agostoni, E. (2018). Mechanical thrombectomy in strokes with large-vessel occlusion beyond 6 hours: A pooled analysis of randomized trials. Journal of Clinical Neurology, 14(3), 407–412. https://doi.org/10.3988/jcn.2018.14.3.407

[ii] Appel, E., Hahn-Goldberg, S., Chow, E., Casaubon, L. K., & Abrams, H. B. (2015). The operational and economic impact of a neurovascular unit in an acute care academic hospital. Canadian Journal of Neurological Sciences, 42(5), 292–298. https://doi.org/10.1017/cjn.2015.32